Inavolisib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 3mg, 9mg
Reference Brands: Itovebi (USA/EU)
Category:
Critical Care
Inavolisib is a targeted oral PI3K-alpha inhibitor used in combination with palbociclib and fulvestrant for treating PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer. It not only inhibits the mutated PI3Kα enzyme but also promotes its degradation, selectively acting on cancer cells with PIK3CA mutations. The drug has shown strong efficacy in prolonging progression-free survival in clinical trials.
Inavolisib is available in Tablets
and strengths such as 3mg, 9mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Inavolisib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Inavolisib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing